Prism Medico

Who are the top shareholders of the Prism Medico?

The top shareholders of Prism Medico are Symbiosis Pharmaceutical Private Limited with 13.99%, followed by public shareholder Vinita Jain at 4.83%. Individual investors collectively own 66.07% of the shares, with no institutional or pledged promoter holdings reported.

The top shareholders of Prism Medico include Symbiosis Pharmaceutical Private Limited, which holds the largest stake at 13.99%. Following that, the highest public shareholder is Vinita Jain, with a holding of 4.83%. Additionally, individual investors collectively hold a significant portion of the company, accounting for 66.07% of the shares. There are no institutional holdings or pledged promoter holdings reported.

Who are in the management team of Prism Medico?

As of March 2022, the management team of Prism Medico includes Sameer Gupta (Company Secretary), Ramandeep Singh (Whole-time Director), Simmi Chhabra (Independent Director), Davender Singh (Director), Pradeep Kumar (Independent Director), Sakshi Laller (Whole-time Director), and Vishwambhar Dayal Gupta (Director). Only Ramandeep Singh has recorded remuneration of Rs. 1.85 lacs, while the others have Rs. 0.

As of March 2022, the management team of Prism Medico includes the following individuals:<BR><BR>1. Sameer Gupta - Company Secretary & Compliance Officer<BR>2. Ramandeep Singh - Whole-time Director<BR>3. Simmi Chhabra - Independent Director<BR>4. Davender Singh - Director<BR>5. Pradeep Kumar - Independent Director<BR>6. Sakshi Laller - Whole-time Director<BR>7. Vishwambhar Dayal Gupta - Director<BR><BR>Ramandeep Singh is the only member with a recorded remuneration of Rs. 1.85 lacs, while the others have a remuneration of Rs. 0.

What does Prism Medico do?

Prism Medico & Pharmacy Ltd is a Non Banking Financial Company focused on investments and share trading, with a market cap of Rs 9 Cr and recent quarterly results showing net sales and profit of 0 Cr. The company was incorporated in 1985 and rebranded in 2012.

Overview:<BR>Prism Medico & Pharmacy Ltd is a Non Banking Financial Company (NBFC) operating in the micro-cap market, primarily engaged in investments, share trading, and financial activities.<BR><BR>History:<BR>The company was originally incorporated as Woolite Mercantile Company Limited in 1985 and changed its name to Prism Medico & Pharmacy Limited on January 9, 2012. The latest quarterly results reported net sales and net profit of 0 Cr for March 2025.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 0 Cr (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap value: Rs 9 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 54<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.00<BR>- Return on Equity: -0.33%<BR>- Price to Book: 0.64<BR><BR>Contact Details:<BR>- Address: D-118 Industrial Area, Phase VII Mohali Punjab : 160055<BR>- Tel: 0172-5020762<BR>- Email: investorgrievancewmcl@gmail.com<BR>- Website: http://www.prismmedico.in

Has Prism Medico declared dividend?

No Dividend History Available

Who are the peers of the Prism Medico?

Prism Medico's peers include Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Trinity League, ISF, and K Z Leasing. Bajaj Finance shows the best performance with a 30.39% return, while Prism Medico has a -29.00% return, higher than ISF's -48.26%.

Peers: The peers of Prism Medico are Bajaj Finance, Jio Financial, Cholaman.Inv.&Fn, Shriram Finance, Muthoot Finance, Libord Securitie, Trinity League, ISF, and K Z Leasing.<BR><BR>Quality Snapshot: Excellent management risk is observed at Bajaj Finance, Cholaman.Inv.&Fn, and Muthoot Finance, while Average management risk is found at Jio Financial, Shriram Finance, and the rest. Good growth is noted at Bajaj Finance, Jio Financial, Shriram Finance, and K Z Leasing, while Average growth is seen at Muthoot Finance, and the rest. Below Average management risk is present at Trinity League, ISF, Prism Medico, and K Z Leasing, with Below Average growth at Prism Medico, Trinity League, and ISF, while Libord Securitie does not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Bajaj Finance at 30.39%, while the lowest is ISF at -48.26%. Prism Medico's 1-year return is -29.00%, which is higher than ISF's but lower than Bajaj Finance's. Additionally, Libord Securitie, Trinity League, ISF, and Prism Medico have negative six-month returns.

What is the technical trend for Prism Medico?

As of May 19, 2025, Prism Medico's technical trend is mildly bearish, with mixed signals across time frames from MACD, moving averages, and Bollinger Bands, indicating a lack of strong momentum.

As of 19 May 2025, the technical trend for Prism Medico has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish. The daily moving averages are mildly bearish, suggesting short-term weakness. Bollinger Bands show a bullish signal on the weekly chart but a mildly bearish signal on the monthly chart, indicating mixed signals across time frames. The KST is mildly bullish weekly but bearish monthly, further contributing to the overall mildly bearish outlook. The Dow Theory shows no clear trend in both weekly and monthly views. Overall, the current technical stance is mildly bearish, reflecting a lack of strong momentum in either direction.

How big is Prism Medico?

As of 24th July, Prism Medico & Pharmacy Ltd has a market capitalization of 9.00 Cr, with recent net sales totaling 41.63 Cr and a net loss of 0.55 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Prism Medico & Pharmacy Ltd has a market capitalization of 9.00 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 41.63 Cr, while the sum of Net Profit for the same period shows a loss of 0.55 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2019. Shareholder's Funds are valued at 12.91 Cr, and Total Assets amount to 21.13 Cr.

Are Prism Medico latest results good or bad?

Prism Medico's latest results are concerning, showing flat performance for Q4 2024 and a 'Strong Sell' rating from MarketsMOJO. However, there are signs of improvement with significant growth in net sales and profit projected for the next quarter, indicating potential for a turnaround.

Prism Medico's latest financial results indicate a challenging situation. The company reported flat performance for the fourth quarter of 2024, showing no significant changes in its financial metrics. This stagnation has led to a 'Strong Sell' rating from MarketsMOJO, suggesting that the market perceives potential difficulties in the company's growth and operational efficiency.<BR><BR>However, looking ahead, there are signs of improvement in the subsequent quarter ending June 2025. The company experienced a remarkable increase in net sales and standalone net profit, with growth rates of 2,171.43% and 1,550.00%, respectively. This upward trend in financial performance could signal a turnaround, but the initial flat results raise concerns about the company's ability to sustain this momentum.<BR><BR>Overall, while the recent quarterly results are not favorable, the significant growth in the following quarter may provide a glimmer of hope for stakeholders. It will be essential to monitor how Prism Medico navigates its challenges in the evolving healthcare sector.

When is the next results date for Prism Medico?

The next results date for Prism Medico is 14 November 2025.

The next results date for Prism Medico is scheduled for 14 November 2025.

How has been the historical performance of Prism Medico?

Prism Medico experienced significant growth in net sales, rising from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19, but faced profitability challenges with a declining operating profit margin and a negative profit before tax in Mar'19. Total assets increased to 21.13 Cr, alongside rising liabilities, while cash flow remained stagnant with no reported activity.

Answer:<BR>The historical performance of Prism Medico shows significant growth in net sales over the years, increasing from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19. The total operating income followed a similar trend, rising from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19. However, the company has faced challenges with profitability, as indicated by the operating profit margin which decreased from 3.33% in Mar'18 to 0.73% in Mar'19, and the profit before tax turned negative at -0.10 Cr in Mar'19 after a positive 0.07 Cr in Mar'18. Despite these challenges, the profit after tax showed a slight recovery to 0.04 Cr in Mar'19 from a loss in the previous years. The total assets increased from 17.26 Cr in Mar'17 to 21.13 Cr in Mar'19, while total liabilities also rose from 15.80 Cr in Mar'18 to 21.13 Cr in Mar'19, indicating a growing financial base but also increasing obligations. The cash flow results indicate no cash inflow or outflow from operating, investing, or financing activities for the years reported.<BR><BR>Breakdown:<BR>Prism Medico's financial performance has demonstrated a remarkable increase in net sales, which surged from 5.28 Cr in Mar'17 to 54.73 Cr in Mar'19, reflecting a strong growth trajectory. The total operating income mirrored this growth, reaching 54.73 Cr in Mar'19. However, the company struggled with profitability, as evidenced by a decline in operating profit margin from 3.33% in Mar'18 to 0.73% in Mar'19, and a negative profit before tax of -0.10 Cr in Mar'19, contrasting with a profit of 0.07 Cr in the prior year. Despite these setbacks, the profit after tax improved to 0.04 Cr in Mar'19, following losses in earlier years. On the balance sheet, total assets rose from 17.26 Cr in Mar'17 to 21.13 Cr in Mar'19, while total liabilities increased correspondingly from 15.80 Cr to 21.13 Cr, indicating a growing but leveraged financial position. The cash flow statements reveal no activity in cash flows from operations, investments, or financing, suggesting a stagnant cash position during this period.

Is Prism Medico overvalued or undervalued?

As of November 20, 2025, Prism Medico is considered undervalued with a valuation grade of very attractive, featuring a PE Ratio of 18.81, an EV to EBIT of 11.40, and a Price to Book Value of 0.76, significantly lower than peers like Max Healthcare and Apollo Hospitals, while maintaining a positive long-term outlook with a 3Y return of 77.32%.

As of 20 November 2025, Prism Medico's valuation grade has moved from fair to very attractive, indicating a significant improvement in its investment appeal. The company is currently considered undervalued. Key ratios include a PE Ratio of 18.81, an EV to EBIT of 11.40, and a Price to Book Value of 0.76, which suggest that the stock is trading at a discount relative to its earnings and book value.<BR><BR>In comparison to its peers, Prism Medico's PE Ratio of 18.81 is markedly lower than that of Max Healthcare, which stands at 80.46, and Apollo Hospitals at 63.94, both of which are classified as very expensive. Additionally, Prism Medico's EV to EBITDA ratio of 11.40 aligns with its valuation grade, reinforcing its attractiveness in the market. Despite recent underperformance against the Sensex, particularly in the 1Y and YTD periods, the long-term outlook remains positive with a 3Y return of 77.32%, suggesting potential for recovery and growth.

Should I buy, sell or hold Prism Medico & Pharmacy Ltd?

Which are the latest news on Prism Medico?

Why is Prism Medico & Pharmacy Ltd falling/rising?

As of 20-May, Prism Medico & Pharmacy Ltd's stock price is at Rs 30.19, reflecting a 3.04% increase and significant year-to-date growth of 58.89%. Despite a decline in investor participation, the stock's performance remains strong relative to the market.

As of 20-May, Prism Medico & Pharmacy Ltd's stock price is rising, currently at Rs 30.19, which reflects an increase of Rs 0.89 or 3.04%. This upward movement is supported by the stock outperforming its sector by 3.12% today and achieving a consecutive gain over the last two days, with a total return of 7.31% during this period. Additionally, the stock reached an intraday high of Rs 30.75, marking a rise of 4.95%.<BR><BR>In the context of broader performance, the stock has shown significant year-to-date growth of 58.89%, contrasting sharply with the Sensex, which has declined by 11.62% during the same timeframe. Over the past year, Prism Medico & Pharmacy Ltd has increased by 95.91%, while the Sensex has fallen by 7.23%. These figures indicate a strong overall performance relative to the market.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 25.73% against the 5-day average. Despite this, the stock remains liquid enough for trading, suggesting that the recent price rise is driven by positive market sentiment and performance metrics rather than high trading volume.